Table 2 Clinical characteristics of improved and non-improved groups of the patients with HBV-ACLF before and after the third treatment of ALSS

Demographics

 Age (years)

45.42 ± 15.12

46.7 ± 13.71

45.42 ± 15.12

46.7 ± 13.71

0.838

-

 Sex (male/female)

10/2

8/2

10/2

8/2

0.840

-

Laboratory data

 HB (g/L)

118.00 ± 21.17

125.50 ± 16.27

113.17 ± 23.51

111.60 ± 10.87

0.370

0.772

 PLT (10⁹/L)

83.08 ± 29.54

116.40 ± 45.45

70.08 ± 30.20

66.20 ± 23.42

0.051

1.000

 TP (g/L)

55.21 ± 5.90

55.81 ± 5.11

54.83 ± 5.25

53.80 ± 5.03

0.806

0.539

 ALB (g/L)

29.63 ± 2.75

31.25 ± 2.68

31.98 ± 4.69

32.43 ± 2.95

0.180

0.497

 ALT (U/L)

154.28 ± 182.54

475.80 ± 383.12

58.17 ± 31.46

67.00 ± 39.31

0.018

0.674

 AST (U/L)

89.25 ± 44.70

198 ± 149.12

51.67 ± 24.91

56.20 ± 35.97

0.073

0.974

 TB (μmol/L)

355.75 ± 105.69

335.28 ± 103.54

167.75 ± 74.70

282.95 ± 106.44

0.653

0.003

 DB (μmol/L)

249.63 ± 88.34

242.00 ± 88.63

131.55 ± 54.11

184.10 ± 53.29

0.843

0.025

 Cr (μmol/L)

65.75 ± 22.76

63.70 ± 21.41

61.58 ± 15.48

59.90 ± 17.02

0.831

0.628

 GFR (mL/min)

109.00 ± 22.77

108.43 ± 18.72

113.07 ± 16.90

111.28 ± 18.84

0.950

0.923

 UA (μmol/L)

143.75 ± 70.90

110.30 ± 40.27

133.25 ± 35.81

116.00 ± 43.83

0.201

0.203

 INR

1.89 ± 0.33

2.59 ± 0.66

1.70 ± 0.27

2.31 ± 0.63

0.010

0.011

 PT (s)

20.76 ± 3.21

27.65 ± 7.36

19.18 ± 2.96

25.59 ± 7.08

0.018

0.021

 AFP (ng/mL)

228.45 ± 224.14

210.60 ± 318.02

-

-

0.881

-

 LA (mmol/l)

2.52 ± 0.47

3.29 ± 0.88

1.6 ± 0.22

2.74 ± 0.55

0.028

< 0.001

Score

 MELD

25.08 ± 2.90

28.80 ± 2.89

20.75 ± 2.95

26.00 ± 3.97

0.007

0.003

 AARC

8.83 ± 1.26

10.10 ± 1.28

6.42 ± 0.66

9.80 ± 2.09

0.032

< 0.001

 HBV-DNA

1.50*10⁷ ± 1.32*10⁷

3.03*10⁷ ± 1.72*10⁷

6.78*10⁶ ± 6.48*10⁶

2.56*10⁷ ± 1.64*10⁷

0.485

0.283

ACLF grade

 I/II/III

1/10/1

0/7/3

12/0/0

0/6/4

0.306

< 0.001